Drug development is by its very nature a high risk based investment opportunity. Balancing that risk, is the potential to discover and develop the next ‘blockbuster’ drug with the consequent high levels of revenue and corresponding company valuation.
Large pharmaceutical companies are increasingly licensing oncology products at earlier stages in the development cycle due to a dearth of opportunities from their own R & D efforts.
The company will be seeking licensing partners at a point in the development cycle (e.g. Phase I clinical results), which maximises the return of investment to shareholders, whilst minimising the investment required.
Do you have an investment or communication enquiry?
Please fill in the form below: